Irisin-Associated Neuroprotective and Rehabilitative Strategies for Stroke

被引:0
|
作者
Melissa Ann Huberman
Nathan D. d’Adesky
Qismat Bahar Niazi
Miguel A. Perez-Pinzon
Helen M. Bramlett
Ami P. Raval
机构
[1] University of Miami,Peritz Scheinberg Cerebral Vascular Disease Research Laboratory, Department of Neurology, Leonard M. Miller School of Medicine
[2] University of Miami,Department of Neurological Surgery, Leonard M. Miller School of Medicine
[3] Bruce W. Carter Department of Veterans Affairs Medical Center,undefined
来源
NeuroMolecular Medicine | 2022年 / 24卷
关键词
Fibronectin type III domain-containing protein 5 (FNDC5); Menopause; Stroke; Low frequency whole-body vibration (LFV); Physical exercise;
D O I
暂无
中图分类号
学科分类号
摘要
Irisin, a newly discovered protein hormone that is secreted in response to low frequency whole body vibration (LFV), could be a promising post-stroke rehabilitation therapy for patients who are frail and cannot comply with regular rehabilitation therapy. Irisin is generated from a membrane-bound precursor protein fibronectin type III domain-containing protein 5 (FNDC5). Aside from being highly expressed in muscle, FNDC5 is highly expressed in the brain. The cleaved form of FNDC5 was found in the cerebrospinal fluid as well as in various regions of the brain. Numerous studies suggest that irisin plays a key role in brain metabolism and inflammation regulation. Both the metabolism and inflammation govern stroke outcome, and in a published study, we demonstrated that LFV therapy following middle cerebral artery occlusion significantly reduced innate immune response, improved motor function and infarct volume in reproductively senescent female rats. The observed effect of LFV therapy could be working via irisin, therefore, the current review focuses to understand various aspects of irisin including its mechanism of action on the brain.
引用
收藏
页码:62 / 73
页数:11
相关论文
共 50 条
  • [41] Current medical and rehabilitative aspects of stroke - Foreword
    Dafer, Rima M.
    Biller, Jose
    TOPICS IN STROKE REHABILITATION, 2008, 15 (01) : V - V
  • [42] Early rehabilitative intervention for stroke - Prospective study
    Ishida, A
    Tanaka, H
    Toyokura, M
    Izumi, S
    1ST WORLD CONGRESS OF THE INTERNATIONAL SOCIETY OF PHYSICAL AND REHABILITATION MEDICINE (ISPRM I), 2001, : 499 - 504
  • [43] Irisin-the future of ischemic stroke therapy?
    Grzeskiewicz, Magda
    Kobak, Joanna Elzbieta
    Drewniak, Hubert
    Terlecki, Piotr
    Przywara, Stanislaw
    ACTA ANGIOLOGICA, 2023, 29 (01): : 19 - 24
  • [44] Effects of Therapeutic Hypothermia Combined with Other Neuroprotective Strategies on Ischemic Stroke: Review of Evidence
    Zhang, Zheng
    Zhang, Linlei
    Ding, Yuchuan
    Han, Zhao
    Ji, Xunming
    AGING AND DISEASE, 2018, 9 (03): : 507 - 522
  • [45] Alzheimer's Disease-Associated Neurotoxic Mechanisms and Neuroprotective Strategies
    Pereira, C.
    Agostinho, P.
    Moreira, P., I
    Cardoso, S. M.
    Oliveira, C. R.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2005, 4 (04) : 383 - 403
  • [46] Neuroprotective strategies in acute ischemic stroke: A narrative review of recent advances and clinical outcomes
    Zhao, Min
    Qiao, Yue
    Weiss, Alexander
    Zhao, Wenbo
    BRAIN CIRCULATION, 2024, 10 (04) : 296 - 302
  • [47] Future neuroprotective strategies
    Saettler, Muriel B.
    Baehr, Mathias
    EXPERIMENTAL NEUROLOGY, 2010, 225 (01) : 40 - 47
  • [48] Nonpharmacologic and Rehabilitative Strategies to Address Chronic Pain
    Choi, Hiu Ying Joanna
    PRIMARY CARE, 2022, 49 (03): : 403 - 413
  • [49] Neuroprotective strategies in epilepsy
    Carlen, PL
    Pelletier, MR
    Ouanounou, A
    Tymianski, M
    Zhang, L
    INTRACTABLE SEIZURES: DIAGNOSIS, TREATMENT AND PREVENTION, 2002, 497 : 209 - 224
  • [50] Neuroprotective Strategies in Glaucoma
    Gossman, Cynthia A.
    Christie, John
    Webster, Mark K.
    Linn, David M.
    Linn, Cindy L.
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (14) : 2178 - 2192